CASE STUDY
European Asset Due Diligence
Bringing European markets’ price, access and reimbursement insight to support global in-licensing decisions
Situation
A major global pharma company was considering therapy area expansion through in-licensing
The global Business Development team recognised the need for European HTA, price & reimbursement insights but the in-house European market access team lacked bandwidth to respond quickly
Action
AESARA deployed a team of industry-veteran strategy consultants and payer researchers to:
- Execute a 4-week project, combining secondary and primary research with experience-based AESARA analysis,
- Quickly and succinctly assess the European value & access opportunity for the asset
- Test product value and price assumptions via double-blind interviews with European HCPs and payers/HTA advisors
- Identify the BD&L implications for client decision-makers
Enabling Activity
Training development & delivery
Region
Europe
Client
Global Head of HEOR
IMPACT
A timely, clear and well-presented report covering,
for priority European markets:
- Market size/opportunity
- HTA insights
- TPP value
- Price potential
Enabled executive decision on go/no-go for the opportunity
